| General Information |
| Business: |
Note: This is a stock-only SPAC IPO – an exception to the usual structure. A SPAC IPO typically consists of a share of common stock and a warrant or a right to acquire a share (or a fraction of a share) of stock upon the consummation of the SPAC’s initial business combination.
We are a newly organized blank check company. We intend to focus on the biotech sector in our search for a company to acquire.
Albert Cha, M.D., Ph.D., managing partner at Frazier Life Sciences, is our CEO.
Fran Adams, a partner at van den Boom & Associates, is our CFO.
(Note: Frazier Life Sciences Acquisition Corp. II filed its S-1 for its SPAC IPO on Sept. 23, 2026, and disclosed the terms: 7.5 million shares at $10.00 each to raise $75 million.)
|
| Industry: |
BLANK CHECKS |
| Employees: |
0 |
| Founded: |
2026 |
| Contact Information |
| Address |
1001 Page Mill Road, Building 4, Suite 200B Palo Alto, CA 93404 |
| Phone Number |
(650) 325-5156 |
| Web Address |
|
| View Prospectus: |
Frazier Life Sciences Acquisition II (Stock-Only) |
| Financial Information |
| Market Cap |
$96.75mil |
| Revenues |
$0.0 mil (last 12 months) |
| Net Income |
$0.0 mil (last 12 months) |
| IPO Profile |
| Symbol |
FLSC |
| Exchange |
NASDAQ |
| Shares (millions): |
7.5 |
| Price range |
$10.00 - $10.00 |
| Est. $ Volume |
$75.0 mil |
| Manager / Joint Managers |
Jefferies |
| CO-Managers |
|
| Expected To Trade: |
|
|
Status:
|
TBA |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |
